Susquehanna International Group’s Altamira Therapeutics Ltd CYTO Stock Holding History

Susquehanna International Group’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-505	Closed	-$49K	–	13869
2022 Q4	$49K	Buy	+505	New	+$58.7K	﹤0.01%	11409
2022 Q1	–	Sell	-92	Closed	-$67K	–	14289
2021 Q4	$67K	Buy	92 +48	+109%	+$32.2K	﹤0.01%	12412
2021 Q3	$35K	Sell	44 -80	-65%	-$90.1K	﹤0.01%	12457
2021 Q2	$177K	Sell	124 -85	-41%	-$117K	﹤0.01%	11718
2021 Q1	$291K	Buy	+209	New	+$280K	﹤0.01%	10671

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's CYTO Position: Q4 2023 in Review

Susquehanna International Group sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2023, closing a stake of 509 shares — an estimated $2.46K sold.

Susquehanna International Group first reported a position in CYTO in Q4 2017 and held it in 9 quarters. The position peaked at $115K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYTO as of Q4 2023.

Susquehanna International Group reported no remaining Altamira Therapeutics Ltd position as of Q4 2023 after selling out during the quarter.
Susquehanna International Group sold 509 Altamira Therapeutics Ltd shares in Q4 2023, an estimated $2.46K.
Susquehanna International Group first reported a position in Altamira Therapeutics Ltd in Q4 2017 and held it in 9 quarters.
Susquehanna International Group's Altamira Therapeutics Ltd position peaked at $115K in Q4 2021.
4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.